As of January 1, 2024, 34 percent of Alzheimer’s disease drugs in clinical trial phase III of development worldwide addressed neurotransmitter receptor mechanisms. This statistic illustrates Alzheimer’s disease drugs in phase III of development worldwide as of early 2024, by type.
Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Alzheimer's Association. (April 24, 2024). Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type [Graph]. In Statista. Retrieved March 15, 2025, from https://www.statista.com/statistics/1173707/alzheimer-disease-therapies-phase-iii-development-type/?__sso_cookie_checker=failed
Alzheimer's Association. "Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type." Chart. April 24, 2024. Statista. Accessed March 15, 2025. https://www.statista.com/statistics/1173707/alzheimer-disease-therapies-phase-iii-development-type/?__sso_cookie_checker=failed
Alzheimer's Association. (2024). Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type. Statista. Statista Inc.. Accessed: March 15, 2025. https://www.statista.com/statistics/1173707/alzheimer-disease-therapies-phase-iii-development-type/?__sso_cookie_checker=failed
Alzheimer's Association. "Alzheimer’s Disease Drugs in Clinical Trial Phase Iii Worldwide as of 2024, by Type." Statista, Statista Inc., 24 Apr 2024, https://www.statista.com/statistics/1173707/alzheimer-disease-therapies-phase-iii-development-type/?__sso_cookie_checker=failed
Alzheimer's Association, Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type Statista, https://www.statista.com/statistics/1173707/alzheimer-disease-therapies-phase-iii-development-type/?__sso_cookie_checker=failed (last visited March 15, 2025)
Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type [Graph], Alzheimer's Association, April 24, 2024. [Online]. Available: https://www.statista.com/statistics/1173707/alzheimer-disease-therapies-phase-iii-development-type/?__sso_cookie_checker=failed
